Status:
COMPLETED
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
Sanofi
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients. Pati...
Detailed Description
The results of several studies suggests than the AT1 receptor antagonists of angiotensin II have inhibitory effects on TGF-beta 1 production and can limit the progression of liver fibrosis. Therefore...
Eligibility Criteria
Inclusion
- age between 18 and 75 years
- liver biopsy performed (less 18 month before inclusion), fibrosis score F2,F3 or F3+ in Metavir classification,
- patients without antiviral therapy
- contraindication to anti viral treatment
- non responders or relapsers patients to past antiviral treatment
Exclusion
- hepatocellular carcinoma
- HIV
- alcool abuser
- cirrhosis
- anti-fibrotic treatment
- pregnancy or breast feeding
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT00265642
Start Date
October 1 2006
End Date
November 1 2013
Last Update
February 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers, Service d'hépato-gastroentérologie
Angers, France, 49933 cedex 09